-+ 0.00%
-+ 0.00%
-+ 0.00%

DEFINIUM THERAPEUTICS RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR DT120 (LYSERGIDE) ORALLY DISINTEGRATING TABLET (ODT) IN MAJOR DEPRESSIVE DISORDER (MDD) FOLLOWING POSITIVE PHASE 3 RESULTS

Reuters·09/08/2026 11:00:00

Please log in to view news